Use of hormone replacement therapy in Washington State: is prevention being put into practice?
The Journal of family practice
confidence
Key findings
71% used HRT; women most likely to benefit (osteoporosis, CHD risk) were not more likely to use HRT; survey of attitudes/practice patterns, no clinical endpoints.
View source on PubMed (PMID 10334613) ↗
- Sample size
- 2023 women
- Population
- Women aged 50 to 70 years from 46 physicians' practices in the Puget Sound region, Washington State
- Dosing
- Not reported
- Duration
- Not reported (survey-based cross-sectional study)
- Route
- Not reported
- Blinding
- not_reported
- Controls
- none
- Drug class
- estrogen therapy
Full abstract
American women are using hormone replacement therapy (HRT) for long-term disease prevention, as well as symptom control, in increasing numbers. Our study examined the role of prevention in women's decisions to initiate HRT and their intended duration of therapy. We analyzed the mailed survey responses of 2023 women aged 50 to 70 years from the practices of 46 physicians in the Puget Sound region for knowledge and attitudes about HRT, current use, and intended duration of therapy. Multiple logistic regression was used to model current HRT use and intended treatment length. A total of 71% of our respondents were using HRT. Women with osteoporosis, coronary heart disease (CHD), or risk factors for CHD were not more likely to be using HRT, and women with CHD or risk factors for CHD were not targeted by their physicians for discussion of HRT. Of women using HRT, 77% expected lifelong use, and this was not more common among women initiating HRT for disease prevention. Despite the high rates of HRT use and expected lifelong duration, use of HRT for prevention was neither higher among women most likely to benefit nor a major determinant of expected lifetime use.